

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria; Virginia 22313-1450

APPLICATION NO.	FILING DAT	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/695,446	10/24/200	Suzana Petanceska	0630/1G184-US1	2608	
32801	7590 07/	2003			
	DARBY P.C.	EXAM	EXAMINER		
P.O. BOX 52 NEW YORK	257 L, NY 10150-525		WARE,	WARE, TODD	
			ART UNIT	PAPER NUMBER	
			1615		
			DATE MAILED: 07/02/2003	,	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/695,446	PETANCESKA ET AL.
Office Action Summary	Examiner	Art Unit
	Todd D Ware	1615
The MAILING DATE of this commun	nication appears on the cover sheet	with the correspondence address
Period for Reply	TOD DEDI V IS SET TO EVDIBE 4	MONTH(S) EDOM
A SHORTENED STATUTORY PERIOD F THE MAILING DATE OF THIS COMMUN Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this community of the period for reply specified above is less than thirty (5). If NO period for reply is specified above, the maximum significant to reply within the set or extended period for reply Any reply received by the Office later than three months are earned patent term adjustment. See 37 CFR 1.704(b). Status	IICATION. s of 37 CFR 1.136(a). In no event, however, may munication. 30) days, a reply within the statutory minimum of tatutory period will apply and will expire SIX (6) May will, by statute, cause the application to become	v a reply be timely filed thirty (30) days will be considered timely. IONTHS from the mailing date of this communication.
1)⊠ Responsive to communication(s) fi	iled on <u>03 <i>January 2003</i></u> .	
,	2b) ☐ This action is non-final.	
3) Since this application is in condition closed in accordance with the practice.		natters, prosecution as to the merits is C.D. 11, 453 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) <u>1-30</u> is/are pending in the	application.	
4a) Of the above claim(s) is/a	are withdrawn from consideration.	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1-30</u> are subject to restricti Application Papers	ion and/or election requirement.	
9) The specification is objected to by th	e Examiner.	
10) The drawing(s) filed on is/are:	: a) ☐ accepted or b) ☐ objected to b	y the Examiner.
Applicant may not request that any ob	ejection to the drawing(s) be held in abo	eyance. See 37 CFR 1.85(a).
11) The proposed drawing correction file	ed on is: a) approved b)	disapproved by the Examiner.
If approved, corrected drawings are re	equired in reply to this Office action.	• •
12) The oath or declaration is objected to	o by the Examiner.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim	n for foreign priority under 35 U.S.C	C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority	documents have been received.	
2. Certified copies of the priority	documents have been received in	Application No
	of the priority documents have been national Bureau (PCT Rule 17.2(a) on for a list of the certified copies n).
14) ☐ Acknowledgment is made of a claim f	•	•
a) The translation of the foreign lar	nguage provisional application has	been received.
Attachment(s)	, ,	
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (F3) Information Disclosure Statement(s) (PTO-1449) P	PTO-948) 5) Notice	ew Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152) .
i. Patent and Trademark Office FO-326 (Rev. 04-01)	Office Action Summary	Part of Paper No. 17

Page 2

Application/Control Number: 09/695,446

Art Unit: 1615

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-6 and 20-25, drawn to methods for reducing amyloid beta or treating a disease through reduction of amyloid beta with an estrogen compound, classified in class 514, subclass 182.
 - II. Claims 7-13, 15-19, and 26-30, drawn to methods for evaluating the ability of a test compound to reduce amyloid beta, classified in class 435, subclass 7.1.
 - III. Claims 14, drawn to a method for evaluating a test compound in a transgenic rodent, classified in class 435, subclass 419.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together and they have different effects. Group I is for treating a disease while Group II is a testing process.
- 3. Inventions I and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In

Page 3

Application/Control Number: 09/695,446

Art Unit: 1615

the instant case the different inventions are not disclosed as capable of use together and they have different effects. Group I is for treating a disease while Group III is a testing process in a transgenic rodent.

- 4. Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together and they have different modes of operation. Group II is a testing process while Group III is a testing process in a transgenic rodent.
- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 6. Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II (this also applies to Group I and Group II as well as Group II and Group III, restriction for examination purposes as indicated is proper.
- 7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Application/Control Number: 09/695,446

Art Unit: 1615

Page 4

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Todd D Ware whose telephone number is (703) 305-1700. The examiner can normally be reached on M-F, 8:30 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703)308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

PATENT EXAMINER

tw

June 30, 2003